Pages

▼
Showing posts with label HCC. Show all posts
Showing posts with label HCC. Show all posts
May 14, 2013

$PVCT CEO Letter: Final MM P2 PV-10 data presented, Systemic immune response shown in multiple cancers

›
The takeaways appear to be: Final MM Phase 2 data finally was reported in 2012, Murine study data, via Moffitt, showed PV-10's sys...
April 23, 2013

$PVCT: HCC & PV-10

›
Towards the end of September 2012, Provectus announced it had expanded the protocol for Phase 1 liver cancer study to include "...th...
April 8, 2013

Potential for 3 #FDA BTD $PVCT Applications

›
Earlier today, Pharmacyclics (NASDAQ:PCYC) announced it received a third Breakthrough Therapy Designation for ibrutinib from the FDA . It wo...
March 8, 2013

$PVCT: Asia - THE Hepatocellular Carcinoma Market

›
November 28, 2012

$PVCT: Liver Cancer Addressable Market in China

›
Though rare in the west, liver cancer is serious in Asia due to the prevalence of hepatitis B infection, which is as high as 10 percent in ...
November 27, 2012

$PVCT: 地理许可证

›
Provectus' share price has bounced above, below and around the 60-cent level following last month's terminated PVCTP "IPO....
November 6, 2012

$PVCT.OB: Mini-Oncology Deal Discussions

›
I have written on this topic in the past. For example, see here . As I understand the lead indications and potential geographies of current ...
November 1, 2012

$PVCT.OB: Blog Reader Questions

›
Would a repeat of the study with HCC and melanoma cell lines  make sense using pancreatic and breast cancer cell lines? If so, would that b...